[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611644":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":32,"responsibleParty":49,"collaborators":51,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":10,"eligibilityCriteria":97,"healthyVolunteers":94,"sex":98,"minAge":99,"maxAge":10,"enrollmentInfo":100,"targetDuration":10,"studyType":103,"phases":10,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"Imperial College London","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"VAPOR2 Participants",null,"6079 participants above the age of 18 years with potential underlying pancreatic cancer referred from primary care according to urgent suspected cancer referral guidelines or referred directly to a pancreatic cancer multidisciplinary team meeting.",[13],"Diagnostic Test: Breath test",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Breath test","All participants will fast for a minimum of six hours prior to breath collection. For participants undergoing a procedure, breath samples must be obtained prior to administration of sedation, anaesthetic or other pharmacological agents. After providing written informed consent, participants will be asked to rinse their mouth with water and then provide a breath sample by exhaling into single-use breath collection bags via a mouthpiece that is subsequently sealed.",[9],[21],{"name":22,"affiliation":5,"role":23},"Professor George B Hanna, PhD, FRCS","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Emma Austin","CONTACT","+44 (0)20 7594 3653","vapor@imperial.ac.uk",{"name":31,"role":27,"phone":28,"phoneExt":10,"email":29},"Caoimhe Walsh, MBBS, MRCS",[33],{"facility":34,"status":35,"city":36,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Imperial College Healthcare NHS Trust","RECRUITING","London","United Kingdom","UK",{"type":40,"coordinates":41},"Point",[42,43],-0.12574,51.50853,{"lat":43,"lon":42},[46,47],{"name":26,"role":27,"phone":10,"phoneExt":10,"email":29},{"name":48,"role":27,"phone":10,"phoneExt":10,"email":29},"Caoimhe Walsh",{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[52,54,55,57,60,62,64,66,68,70,72,74,76,78,80,82,84,86,88,90],{"name":53,"class":6},"Pancreatic Cancer UK",{"name":34,"class":6},{"name":56,"class":6},"Royal Free Hospital NHS Foundation Trust",{"name":58,"class":59},"Liverpool University Hospitals NHS Foundation Trust","OTHER_GOV",{"name":61,"class":6},"Newcastle-upon-Tyne Hospitals NHS Trust",{"name":63,"class":6},"University Hospital Southampton NHS Foundation Trust",{"name":65,"class":6},"Sherwood Forest Hospitals NHS Foundation Trust",{"name":67,"class":6},"Buckinghamshire Healthcare NHS Trust",{"name":69,"class":6},"The Leeds Teaching Hospitals NHS Trust",{"name":71,"class":59},"Dorset County Hospital NHS Foundation Trust",{"name":73,"class":6},"Sheffield Teaching Hospitals NHS Foundation Trust",{"name":75,"class":6},"Kettering General Hospital NHS Foundation Trust",{"name":77,"class":59},"County Durham and Darlington NHS Foundation Trust",{"name":79,"class":6},"North Tees and Hartlepool NHS Foundation Trust",{"name":81,"class":6},"University Hospital Birmingham NHS Foundation Trust",{"name":83,"class":59},"Betsi Cadwaladr University Health Board",{"name":85,"class":6},"Northampton General Hospital NHS Trust",{"name":87,"class":59},"NHS Fife",{"name":89,"class":6},"Somerset NHS Foundation Trust",{"name":91,"class":6},"Aneurin Bevan University Health Board","100611644","volatile-organic-compound-assessment-in-pancreatic-ductal-adenocarcinoma-vapor2-100611644",false,"NCT07243262","Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)","Inclusion Criteria:\n\n* Adult participants ≥ 18 years old\n* Referral from primary care according to the urgent suspected cancer referral guidelines for potential underlying pancreatic cancer, or referral directly to a pancreatic cancer multidisciplinary team meeting\n\nExclusion Criteria:\n\n* Previous pancreatic resection\n* History of another cancer (other than non-melanoma skin cancers) within three years\n* Pregnant participants (pregnancy status to be confirmed verbally with the participant)\n* Participants with co-morbidities preventing breath collection\n* Unable or unwilling to provide informed consent","ALL","18 Years",{"count":101,"type":102},6079,"ESTIMATED","OBSERVATIONAL","The investigators are developing a non-invasive breath test to help us detect pancreatic cancer earlier. The test detects small molecules called volatile organic compounds that are made by pancreatic cancers.\n\nPancreatic cancer is a rare disease but patients are often diagnosed at a late stage because their symptoms are the same as those of many common illnesses. This makes it hard for doctors to know which patients need to be tested for pancreatic cancer. If the investigators find pancreatic cancer at a late stage, it reduces the number of treatment choices for patients.\n\nOur test could be offered to patients who are experiencing vague symptoms, which might be caused either by pancreatic cancer or a common illness. This test could help doctors to identify which of those patients may have pancreatic cancer, and ensure they get referred for specialised pancreatic cancer tests. The investigators hope that this will allow us to diagnose pancreatic cancer earlier, increasing treatment choices for patients and improving survival from pancreatic cancer.\n\nThe investigators have previously conducted a study (VAPOR1) which collected breath samples from people with and without pancreatic cancer. When the investigators analysed these samples, they found that there is a difference in the volatile organic compounds breathed out by people who have pancreatic cancer compared to those that do not. The investigators used these 'markers' to develop a breath test to diagnose pancreatic cancer. In VAPOR2, the investigators will study our breath test in a much larger group of patients who have been referred for further investigations for potential underlying pancreatic cancer to see how accurately it can pick up the small percentage of people who have pancreatic cancer.",[106,107],"Pancreatic Cancer","PDAC - Pancreatic Ductal Adenocarcinoma",[109,110,111,112,113],"Volatile organic compounds (VOCs)","Breath analysis","Volatolomics","Validation","Early detection of cancer","2026-05-15",{"date":116,"type":117},"2026-05-19","ACTUAL",{"date":119,"type":117},"2025-10-21",{"date":121,"type":102},"2028-08-01",{"name":5,"class":6},1]